The vaccine induced a significant increase in spike-specific CD4+ T-cell levels in both infection-naive (1.76-fold, p = 0.014, Wilcoxon signed rank test) and convalescent patients (1.86-fold, p = 0.006, Wilcoxon signed rank test). This evidence concerns the gene CD4 and infection.